EMERGENT BIOSOLUTIONS INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
EMERGENT BIOSOLUTIONS INC. (EBS) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $114.90 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $114.90M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $108.70M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $58.70M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $14.80M; Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed $15.30M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $114.90M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $108.70M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $58.70M 10-K · filed 2025-03-04 | |
| 2022-12-31 | $14.80M 10-K · filed 2024-03-08 | $15.30M 10-K · filed 2023-03-01 |
| 2021-12-31 | $7.60M 10-K/A · filed 2023-12-11 | |
| 2020-12-31 | $8.10M 10-K · filed 2022-02-25 | |
| 2019-12-31 | $8.50M 10-K · filed 2021-02-19 | |
| 2018-12-31 | $10.70M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |